Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

This review explores recent findings on regulatory T cells, focusing on their unique functions in non-lymphoid tissues and new mechanisms of action, but presents no original clinical results.

This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.

This review discusses the roles of αβ and γδ T cells in skin health and disease and reports no new clinical results; the authors highlight potential therapeutic developments.

This article reviews therapy-related hair disorders in oncology patients, detailing underlying mechanisms and potential management strategies, but reports no new clinical findings.

This study reported that targeted anticancer therapies are associated with an increased risk of alopecia compared to placebo, although the risk was lower compared to chemotherapy.

The authors describe drug repurposing as a promising strategy for finding new uses for existing drugs, noting it is efficient, cost-effective, and poses lower risks than traditional drug discovery processes, potentially aiding in the treatment of rare and difficult-to-treat diseases.

In this study, iNKT10 cells were found to play a significant role in preventing and treating alopecia areata in a humanized mouse model, suggesting these cells could have potential in managing related autoimmune disorders.

This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.

This review discusses the clinical characteristics of alopecia in cancer patients, highlighting its potential role as an associated finding or diagnostic clue, but reports no new clinical results.

This review discusses recent developments in targeted melanoma therapies, including BRAF/MEK/ERK pathway inhibitors and challenges like resistance and skin toxicities, but reports no new clinical results.

This article compares the immunology of cancer and the placenta and suggests that immunotherapy for pregnant cancer patients could be feasible with careful exploration, though no new clinical results are reported.

This review discusses multiple pathways through which exosomes may regulate skin functions and diseases like melanoma, scleroderma, and pigmentation disorders, without providing new clinical results; future therapeutic strategies are suggested.

This article reviews common skin reactions associated with epidermal growth factor receptor inhibitors and reports no new clinical findings, emphasizing the need for understanding nursing care and oncodermatology.

This article discusses the role of external beam radiotherapy as a primary treatment method for cancer and reports no new clinical findings.

This study explored the immune environment of the hair follicle's bulge region and suggested that its unique signaling may prevent melanoma formation by lacking necessary proinflammatory signals for full oncogenic transformation, indicating potential strategies for melanoma prevention by replicating this immune-privileged environment.

This article reviews the identification and assessment of cutaneous drug reactions, emphasizing the importance of early recognition and the need for accurate diagnosis to prevent serious complications; it reports no new clinical results.

This review examines the potential of regulatory T cell-based therapies to transform treatment across various medical specialties by promoting immune tolerance and tissue repair, but it reports no new clinical results.

This study outlines the temporary or sometimes permanent hair loss caused by cancer treatments, noting it often starts 2-3 weeks after chemotherapy and highlights the need for more research into prevention and treatment strategies for therapy-related alopecia.

This study describes changes in scalp hair color, including rare instances of repigmentation, following volumetric modulated arc therapy for skin cancer; this potential side effect may warrant discussion during informed consent.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

This study identified numerous drugs with potential to trigger vitiligo, cautioning that these pharmacovigilance findings need further validation and that patients on these medications should be monitored for vitiligo development.

This study provides an analysis of global publications on TLS, offering insights into the role of TLS in immunotherapy and suggesting future research directions.

This review discusses the adverse effects on hair associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for comprehensive documentation of these effects.

This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.

This study suggests that while complementary and alternative treatments for hair loss are becoming more popular, their effectiveness and mechanisms remain largely unverified.

Men with a certain type of hair loss often use facial moisturizers, and a specific antibiotic treatment may help another hair condition.

Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.

This narrative review analyzed the literature on premature hair graying, identifying potential contributors such as nutrient deficiencies, oxidative and emotional stress, smoking, genetic factors, autoimmune diseases, and medication side effects, but reported no effective treatment to reverse it, underscoring the necessity for further research.